Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data

References

• Simister NE, Rees AR. Isolation and characterization of an Fc receptor from neonatal rat small intestine. Eur J Immun 1985; 15:733-38; PMID:2988974; http://dx.doi.org/10.1002/eji.1830150718
   PubMed Web of Science ®Google Scholar
• Simister NE, Mostov KE. Cloning and expression of the neonatal rat intestinal Fc receptor, a major histocompatibility complex class I antigen homolog. Cold Spring Harb Symp Quant Biol 1989; 54 Pt 1:571-80; PMID:2534798; http://dx.doi.org/10.1101/SQB.1989.054.01.068
   PubMedGoogle Scholar
• Bjorkman PJ, Parham P. Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem 1990; 59:253-88; PMID:2115762; http://dx.doi.org/10.1146/annurev.bi.59.070190.001345
   PubMed Web of Science ®Google Scholar
• Rodewald, R. Intestinal transport of antibodies in the newborn rat. J Cell Biol 1973; 58:198-211; PMID:4726306; http://dx.doi.org/10.1083/jcb.58.1.189
   Web of Science ®Google Scholar
• Story CM, Mikulska JE, Simister NE. A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J Exp Med 1994; 180:2377-81; PMID:7964511; http://dx.doi.org/10.1084/jem.180.6.2377
   PubMed Web of Science ®Google Scholar
• Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I– related receptor FcRn. Annu Rev Immunol 2000; 18:739-66; PMID:10837074; http://dx.doi.org/10.1146/annurev.immunol.18.1.739
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25; PMID:17703228; http://dx.doi.org/10.1038/nri2155
   PubMed Web of Science ®Google Scholar
• Raghavan M, Bonagura VR, Morrison SL, Bjorkman PJ. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 1995; 34:14649-57; PMID:7578107; http://dx.doi.org/10.1021/bi00045a005
   PubMed Web of Science ®Google Scholar
• Goebl NA, Babbey CM, Datta-Mannan A,Witcher DR, Wroblewski VJ, Dunn KW. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Mol Biol Cell 2008; 19:5490-505; PMID:18843053; http://dx.doi.org/10.1091/mbc.E07-02-0101
   PubMed Web of Science ®Google Scholar
• Ober RJ, Martinez C, Lai X, Zhou J, Ward ES. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci USA 2004; 101:11076-81; PMID: 15258288; http://dx.doi.org/10.1073/pnas.0402970101
   PubMed Web of Science ®Google Scholar
• Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol 2004; 172:2021-9; PMID:14764666; http://dx.doi.org/10.4049/jimmunol.172.4.2021
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Criste R, Dall'Acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP. A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults. Antimicrob Agents Chemother 2013; 57:6147-53; PMID:24080653; http://dx.doi.org/10.1128/AAC.01285-13
   PubMed Web of Science ®Google Scholar
• Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, Lowman HB. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009; 182:7663-71; PMID:19494290; http://dx.doi.org/10.4049/jimmunol.0804182
   PubMed Web of Science ®Google Scholar
• Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). The J Biol Chem 2006; 281:23514-24; PMID:16793771; http://dx.doi.org/10.1074/jbc.M604292200
   PubMed Web of Science ®Google Scholar
• Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006; 176:346-56; PMID:16365427; http://dx.doi.org/10.4049/jimmunol.176.1.346
   PubMed Web of Science ®Google Scholar
• Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010; 28:157-9; PMID:20081867; http://dx.doi.org/10.1038/nbt.1601
   PubMed Web of Science ®Google Scholar
• Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, Lowman HB, Fielder PJ, Prabhu S. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 2010; 38:600-5; PMID:20071453; http://dx.doi.org/10.1124/dmd.109.031310
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Wroblewski VJ. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem 2007; 19;282:1709-17; PMID:17135257; http://dx.doi.org/10.1074/jbc.M607161200
   Web of Science ®Google Scholar
• Gurbaxani B, Dela Cruz LL, Chintalacharuvu K, Morrison SL. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol 2006; 43:1462-73; PMID:16139891; http://dx.doi.org/10.1016/j.molimm.2005.07.032
   PubMed Web of Science ®Google Scholar
• Hötzel I, Theil F-P, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. mAbs. 2012; 4(6):753-60; PMID:23778268; http://dx.doi.org/10.4161/mabs.22189
   PubMed Web of Science ®Google Scholar
• Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13:1551-9; PMID:11717196; http://dx.doi.org/10.1093/intimm/13.12.1551
   PubMed Web of Science ®Google Scholar
• Kelley RF, Meng YG. Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function. Methods Mol Biol 2012; 901:277-93; PMID:22723108; http://dx.doi.org/10.1007/978-1-61779-931-0_18
   PubMedGoogle Scholar
• Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 2002; 169:5171-80; PMID:12391234; http://dx.doi.org/10.4049/jimmunol.169.9.5171
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010; 184:1968-76; PMID:20083659; http://dx.doi.org/10.4049/jimmunol.0903296
   PubMed Web of Science ®Google Scholar
• Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, Pham A, Bolton G, McDonough D, Lindquist K, Pons J, Rajpal A. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. mAbs 2015; 7:331-43; PMID: 25658443; http://dx.doi.org/10.1080/19420862.2015.1008353
   PubMed Web of Science ®Google Scholar
• Neuber T, Frese K, Jaehrling J, Jäger S, Daubert D, Felderer K, Linnemann M, Höhne A, Kaden S, Kölln J, et al. Characterization and screening of IgG binding to the neonatal Fc receptor. mAbs 2014; 6:928-42; PMID:24802048; http://dx.doi.org/10.4161/mabs.28744
   PubMed Web of Science ®Google Scholar
• Huber AH, Kelley RF, Gastinel LN, Bjorkman PJ. Crystallization and stoichiometry of binding of a complex between a rat intestinal Fc receptor and Fc. J Mol Biol 1993; 230:1077-83; PMID:8478919; http://dx.doi.org/10.1006/jmbi.1993.1220
   PubMed Web of Science ®Google Scholar
• Lu Y, Vernes J, Chiang N, Ou Q, Ding J, Adams C, Hong K, Truong B, Ng D, Shen A, et al. Identification of IgG(1) variants with increased affinity to Fcγ RIIIa and unaltered affinity to FcγRI and FcRn: Comparison of soluble receptor-based and cell-based binding assays. J Immunol Methods 2011; 365:132-41; PMID:21185301; http://dx.doi.org/10.1016/j.jim.2010.12.014
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591-604; PMID:11096108; http://dx.doi.org/10.1074/jbc.M009483200
   PubMed Web of Science ®Google Scholar
• Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, Vásquez M, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem. 2004; 279:6213-6; PMID:14699147; http://dx.doi.org/10.1074/jbc.C300470200
   PubMed Web of Science ®Google Scholar
• Mathur A, Arora T, Liu L, Crouse-Zeineddini J, Mukku V. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics. J Immunol Methods 2013; 390:81-91; PMID:23384837; http://dx.doi.org/10.1016/j.jim.2013.01.011
   PubMed Web of Science ®Google Scholar
• Wu Q, Lee HY, Wong PY, Jiang G, Gazzano-Santoro H. Development and applications of AlphaScreen-based FcRn binding assay to characterize monoclonal antibodies. J Immunol Methods 2015; 420:31-7; PMID:25837414; http://dx.doi.org/10.1016/j.jim.2015.03.012
   PubMed Web of Science ®Google Scholar
• Schlothauer T, Rueger P, Stracke JO, Hertenberger H, Fingas F, Kling L, Emrich T, Drabner G, Seeber S, Auer J, et al. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. mAbs 2013; 5:576-86; PMID:23765230; http://dx.doi.org/10.4161/mabs.24981
   PubMed Web of Science ®Google Scholar
• Pollastrini J, Dillon TM, Bondarenko P, Chou RY. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution. Anal Biochem 2011; 414:88-98; PMID:21385563; http://dx.doi.org/10.1016/j.ab.2011.03.001
   PubMed Web of Science ®Google Scholar
• Magistrelli G, Malinge P, Anceriz N, Desmurs M, Venet S, Calloud S, Daubeuf B, Kosco-Vilbois M, Fischer N. Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies. J Immunol Methods 2012; 375:20-9; PMID:21939661; http://dx.doi.org/10.1016/j.jim.2011.09.002
   PubMed Web of Science ®Google Scholar
• Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, Hochman J, Prueksaritanont T. Monoclonal antibodies with identical Fc Sequences Can Bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 2011; 39:1469-77; PMID:21610128; http://dx.doi.org/10.1124/dmd.111.039453
   PubMed Web of Science ®Google Scholar
• Datta-mannan A, Witcher DR, Tang WY, Watkins JD, Jiang W, Wroblewski VJ. Humanized IgG1 Variants With Differential Binding Properties To The Neonatal Fc Receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos 2007; 35:85-94; PMID: 17050651; http://dx.doi.org/10.1124/dmd.106.011734
   Web of Science ®Google Scholar
• Firan M, Bawdon R, Radu C, Ober RJ, Eaken D, Antohe F, Ghetie V, Ward ES. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol 2001; 13:993-1002; PMID:11470769; http://dx.doi.org/10.1093/intimm/13.8.993
   PubMed Web of Science ®Google Scholar
• Yeung YA, Wu X, Reyes AE, Vernes J, Lien S, Lowe J, Maia M, Forrest WF, Meng YG, Damico LA, et al. A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life. Cancer Res 2010; 70:3269-77; PMID:20354184; http://dx.doi.org/10.1158/0008-5472.CAN-09-4580
   PubMed Web of Science ®Google Scholar
• Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, Yao Z, Sreedhara A, Cano T, Tesar DB, et al. Charge variants in IgG1 Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. mAbs 2010; 6:613-24; PMID:20818176; http://dx.doi.org/10.4161/mabs.2.6.13333
   Web of Science ®Google Scholar
• Raghavan M, Wang Y; Bjorkman PJ. Effects of receptor dimerization on the interaction between the class I major histocompatibility complex-related Fc receptor and IgG. Proc Natl Acad Sci USA 1995; 92:11200-04; PMID:7479965; http://dx.doi.org/10.1073/pnas.92.24.11200
   PubMed Web of Science ®Google Scholar
• Vaughn DE, Bjorkman PJ. High-affinity binding of the neonatal Fc receptor to its IgG ligand requires receptor immobilization. Biochemistry 1997; 36:9374-80; PMID:9235980; http://dx.doi.org/10.1021/bi970841r
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Engineering, Design & Selection 2010; 23:385-92; PMID:20159773; http://dx.doi.org/10.1093/protein/gzq009
   PubMed Web of Science ®Google Scholar
• Zhang L, Lilyestrom W, Charlene Li, Thomas Scherer, Robert van Reis, and Boyan Zhang. Revealing a Positive Charge Patch on a Recombinant Monoclonal Antibody by Chemical Labeling and Mass Spectrometry. Anal Chem 2011; 83:8501-08; PMID:22004540; http://dx.doi.org/10.1021/ac2016129
   PubMed Web of Science ®Google Scholar
• Sánchez LM, Penny DM, Bjorkman PJ. Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand. Biochemistry 1999; 38:9471-6; PMID:10413524; http://dx.doi.org/10.1021/bi9907330
   PubMed Web of Science ®Google Scholar
• Huber AH, Kelley RF, Gastinel LN, Bjorkman PJ. Crystallization and stoichiometry of binding of a complex between a rat intestinal Fc receptor and Fc. J Mol Biol 1993; 230:1077-83; PMID:8478919; http://dx.doi.org/10.1006/jmbi.1993.1220
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, Xu X, Theil F, Khawli LA, Leach MW. Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem 2012; 3:73-92; PMID:22558487; http://dx.doi.org/10.4331/wjbc.v3.i4.73
   PubMedGoogle Scholar
• Day YS, Baird CL, Rich RL, Myszka DG. Direct comparison of binding equilibrium, thermodynamic, and rate constants determined by surface- and solution-based biophysical methods. Protein Sci 2002; 11:1017-25; PMID:11967359; http://dx.doi.org/10.1110/ps.4330102
   PubMed Web of Science ®Google Scholar
• Matsumoto-Takasaki A, Hanashima S, Aoki A, Yuasa N, Ogawa H, Sato R, Kawakami H, Mizuno M, H. Nakada, Yamaguchi Y, et al. Surface plasmon resonance and NMR analyses of anti Tn-antigen MLS128 monoclonal antibody binding to two or three consecutive Tn-antigen clusters. J Biochem 2011; 151:273-82; PMID:22161472; http://dx.doi.org/10.1093/jb/mvr138
   PubMed Web of Science ®Google Scholar
• Drake A, Myszka DG, Klakamp SL. Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods. Anal Biochem 2004; 328:35-43; PMID:15081905; http://dx.doi.org/10.1016/j.ab.2003.12.025
   PubMed Web of Science ®Google Scholar
• HoareHL, SullivanLC, Pietra G, Clements CS, Lee EJ, Ely LK, Beddoe T, Falco M, Kjer-Nielsen L, Reid LH, et al. Structural basis for a major histocompatibility complex class Ib–restricted T cell response. Nat Immunol 2006; 7:256-64; PMID:16474394; http://dx.doi.org/10.1038/ni1312
   PubMed Web of Science ®Google Scholar
• Trilling AK, Harmsen MM, Ruigrok VJ, Zuilhof H, Beekwilder J. The effect of uniform capture molecule orientation on biosensor sensitivity: dependence on analyte properties. Biosens Bioelectron 2013; 40:219-26; PMID:22878083; http://dx.doi.org/10.1016/j.bios.2012.07.027
   PubMed Web of Science ®Google Scholar
• Yang J, Wang X, Fuh G, Yu L, Wakshull E, Khosraviani M, Day ES, Demeule B, Liu J, Shire SJ, et al. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Molecular Pharmaceutics 2014; 11:3421-30; PMID:25162961; http://dx.doi.org/10.1021/mp500160v
   PubMed Web of Science ®Google Scholar
• Rich RL, Myszka DG. Survey of the year 2006 commercial optical biosensor literature. J Mol Recognit 2007; 20:300-66; PMID:18074396; http://dx.doi.org/10.1002/jmr.862
   PubMed Web of Science ®Google Scholar
• Gurbaxani B, Dostalek M, Gardner I. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? Mol Immunol. 2013 Dec; 56:660-74; PMID:23917469; http://dx.doi.org/10.1016/j.molimm.2013.05.008
   PubMed Web of Science ®Google Scholar
• Vaughn DE. Identification of critical IgG binding epitopes on the neonatal Fc receptor. J Mol Biol 1997; 274:597-607; PMID:9417938; http://dx.doi.org/10.1006/jmbi.1997.1388
   PubMed Web of Science ®Google Scholar
• Kaufman EN1, Jain RK. Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. Cancer Res. 1992;52:4157-67.
   Google Scholar
• Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A 2015; 112:5997-6002; PMID:25918417; http://dx.doi.org/10.1073/pnas.1408766112
   PubMed Web of Science ®Google Scholar
• Bumbaca Yadav D, Sharma VK, Boswell CA, Hotzel I, Tesar D, Shang Y, Ying Y, Fischer SK, Grogan JL, Chiang EY, et al. Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics. J Biol Chem 2015; 290:29732-41; PMID:26491012; http://dx.doi.org/10.1074/jbc.M115.692434
   PubMed Web of Science ®Google Scholar
• Wong AW, Baginski TK, Reilly DE. Enhancement of DNA uptake in FUT8-deleted CHO cells for transient production of afucosylated antibodies. Biotechnology and Bioengineering 2010; 106:751-63; PMID:20069558; http://dx.doi.org/10.1002/bit.22749
   PubMed Web of Science ®Google Scholar